drug_type
RELEVANT_DRUG
intervention_type
In vivo gene therapy (lentiviral vector)
drug_description
An in vivo gene therapy using a lentiviral vector that delivers a CD20-specific chimeric antigen receptor (CAR20) transgene. Following a single IV infusion, it transduces the patient’s immune cells to generate CAR-T and CAR-NK cells in vivo, which bind CD20 on malignant B cells and mediate cytotoxic killing.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Lentiviral Vectors
drug_category
GENE THERAPY
drug_class
Gene therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
INT2104 is an in vivo lentiviral gene therapy that delivers a CD20-specific CAR transgene (CAR20) to the patient’s immune cells after IV infusion. The transduced T and NK cells express CAR20, recognize CD20 on malignant B cells, form an immune synapse, and mediate cytotoxic killing via perforin/granzyme release and cytokine-driven mechanisms, depleting CD20-positive tumor cells.
drug_name
INT2104
nct_id_drug_ref
NCT06539338